Some U.S. Employers Plan to Drop Coverage for GLP-1 Obesity Drugs
What's happening
A growing number of U.S. employers are considering eliminating insurance coverage for obesity drugs such as Wegovy and Zepbound because of rapidly rising costs. These medications have become extremely popular and effective for weight loss, but their widespread use has created significant expenses for employer-sponsored health plans.
What's changing / Business impact
Many employers are reevaluating whether they can afford to continue covering these drugs as more workers begin using them. Some companies may introduce stricter eligibility requirements, while others may stop covering the medications entirely.
Why this matters
The debate highlights one of the biggest healthcare questions today: who should pay for highly effective but expensive obesity treatments? Patients, insurers, employers, and drug manufacturers all have different perspectives on the issue. As obesity drug use continues growing, coverage decisions could determine how widely these treatments are used.